PDF(Pubmed)
Abstract：
The dipeptidyl peptidase-4 (DPP-4) enzyme significantly influences carcinogenic pathways in the skin. The objective of this study was to determine whether DPP-4 inhibitors are associated with the incidence of melanoma and nonmelanoma skin cancer, compared with sulfonylureas.
Using the United Kingdom Clinical Practice Research Datalink, we assembled two new-user active comparator cohorts for each skin cancer outcome from 2007 to 2019. For melanoma, the cohort included 96 739 DPP-4 inhibitor users and 209 341 sulfonylurea users, and 96 411 DPP-4 inhibitor users and 208 626 sulfonylurea users for non-melanoma skin cancer. Propensity score fine stratification weighted Cox proportional hazards models were used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs of melanoma and non-melanoma skin cancer, separately.
Overall, DPP-4 inhibitors were associated with a 23% decreased risk of melanoma compared with sulfonylureas (49.7 vs 65.3 per 100 000 person-years, respectively; HR 0.77, 95% CI 0.61 to 0.96). The HR progressively reduced with increasing cumulative duration of use (0-2 years HR 1.14, 95% CI 0.84 to 1.54; 2.1-5 years HR 0.44, 95% CI 0.29 to 0.66; >5 years HR 0.33, 95% CI 0.14 to 0.74). In contrast, these drugs were not associated with the incidence of non-melanoma skin cancer, compared with sulfonylureas (448.1 vs 426.1 per 100 000 person-years, respectively; HR 1.06, 95% CI 0.98 to 1.15).
In this large, population-based cohort study, DPP-4 inhibitors were associated with a reduced risk of melanoma but not non-melanoma skin cancer, compared with sulfonylureas.
Using the United Kingdom Clinical Practice Research Datalink, we assembled two new-user active comparator cohorts for each skin cancer outcome from 2007 to 2019. For melanoma, the cohort included 96 739 DPP-4 inhibitor users and 209 341 sulfonylurea users, and 96 411 DPP-4 inhibitor users and 208 626 sulfonylurea users for non-melanoma skin cancer. Propensity score fine stratification weighted Cox proportional hazards models were used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs of melanoma and non-melanoma skin cancer, separately.
Overall, DPP-4 inhibitors were associated with a 23% decreased risk of melanoma compared with sulfonylureas (49.7 vs 65.3 per 100 000 person-years, respectively; HR 0.77, 95% CI 0.61 to 0.96). The HR progressively reduced with increasing cumulative duration of use (0-2 years HR 1.14, 95% CI 0.84 to 1.54; 2.1-5 years HR 0.44, 95% CI 0.29 to 0.66; >5 years HR 0.33, 95% CI 0.14 to 0.74). In contrast, these drugs were not associated with the incidence of non-melanoma skin cancer, compared with sulfonylureas (448.1 vs 426.1 per 100 000 person-years, respectively; HR 1.06, 95% CI 0.98 to 1.15).
In this large, population-based cohort study, DPP-4 inhibitors were associated with a reduced risk of melanoma but not non-melanoma skin cancer, compared with sulfonylureas.
摘要：
背景：二肽基肽酶-4（DPP-4）酶显着影响皮肤中的致癌途径。这项研究的目的是确定DPP-4抑制剂是否与黑色素瘤和非黑色素瘤皮肤癌的发病率相关。与磺酰脲类相比。
方法：使用英国临床实践研究数据链，从2007年到2019年,我们为每个皮肤癌结局收集了两个新用户主动比较队列.对于黑色素瘤，该队列包括96739名DPP-4抑制剂使用者和209341名磺酰脲使用者，96411名DPP-4抑制剂使用者和208626名磺酰脲类药物使用者用于非黑色素瘤皮肤癌。倾向评分精细分层加权Cox比例风险模型用于估计95%置信区间的风险比（HR）（黑色素瘤和非黑色素瘤皮肤癌的CI，分开。
结果：总体而言，与磺酰脲类相比，DPP-4抑制剂可降低23％的黑色素瘤风险（49.7vs65.3/100000人年，分别为；HR0.77，95%CI0.61至0.96）。HR随着累积使用时间的增加而逐渐降低（0-2年HR1.14，95％CI0.84至1.54；2.1-5年HR0.44，95％CI0.29至0.66；>5年HR0.33，95％CI0.14至0.74）。相比之下,这些药物与非黑色素瘤皮肤癌的发病率无关，与磺酰脲类相比(每10万人年448.1对426.1，分别为；HR1.06，95%CI0.98至1.15）。
结论：在这个大的，基于人群的队列研究，DPP-4抑制剂与黑色素瘤的风险降低有关，但与非黑色素瘤皮肤癌的风险无关。与磺酰脲类相比。
方法：使用英国临床实践研究数据链，从2007年到2019年,我们为每个皮肤癌结局收集了两个新用户主动比较队列.对于黑色素瘤，该队列包括96739名DPP-4抑制剂使用者和209341名磺酰脲使用者，96411名DPP-4抑制剂使用者和208626名磺酰脲类药物使用者用于非黑色素瘤皮肤癌。倾向评分精细分层加权Cox比例风险模型用于估计95%置信区间的风险比（HR）（黑色素瘤和非黑色素瘤皮肤癌的CI，分开。
结果：总体而言，与磺酰脲类相比，DPP-4抑制剂可降低23％的黑色素瘤风险（49.7vs65.3/100000人年，分别为；HR0.77，95%CI0.61至0.96）。HR随着累积使用时间的增加而逐渐降低（0-2年HR1.14，95％CI0.84至1.54；2.1-5年HR0.44，95％CI0.29至0.66；>5年HR0.33，95％CI0.14至0.74）。相比之下,这些药物与非黑色素瘤皮肤癌的发病率无关，与磺酰脲类相比(每10万人年448.1对426.1，分别为；HR1.06，95%CI0.98至1.15）。
结论：在这个大的，基于人群的队列研究，DPP-4抑制剂与黑色素瘤的风险降低有关，但与非黑色素瘤皮肤癌的风险无关。与磺酰脲类相比。
